Atopy: A patient-specific risk factor for diffuse lamellar keratitis

被引:31
作者
Boorstein, SM
Henk, HJ
Elner, VM
机构
[1] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA
[2] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA
[3] Dean Fdn, Madison, WI USA
[4] Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA
[5] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0161-6420(02)01287-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To identify whether atopy is a patient-specific risk factor for the development of diffuse lamellar keratitis (DLK) after laser in situ keratomileusis (LASIK). Design: Retrospective survey study. Participants: Three hundred sixty consecutive patients who underwent same-day bilateral myopic astigmatic primary LASIK procedures during March 1, 2000, through July 31, 2000. Methods: We collected data for 360 consecutive patients undergoing LASIK during a 4-month period. On preoperative medical history questionnaires, patients self-identified whether they were atopic. All patients also indicated whether they were taking antiallergy medications or were untreated for allergy. Main Outcome Measures: The incidence of DLK after LASIK surgery. Results: The risk of DLK in untreated atopic patients was much greater than the risk of DLK among nonatopics (odds ratio, 5.85; 95% confidence interval, 2.89-11.85; P = 0.001). However, the risk of DLK among atopic patients taking an oral systemic nonsedating histamine receptor 1 antagonist and among nonatopic patients did not differ significantly (odds ratio, 0.54; 95% confidence interval, 0.12-2.46; P = 0.43). Conclusions: Atopy is a patient-specific risk factor for the development of DLK after primary bilateral LASIK for either myopia or myopic astigmatism. Atopic individuals benefit from preoperative treatment to minimize the incidence of DLK and the potential for visual loss. (C) 2003 by the American Academy of Ophthalmology.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 49 条
[1]   THE INFLUX OF INFLAMMATORY CELLS INTO NASAL WASHINGS DURING THE LATE RESPONSE TO ANTIGEN CHALLENGE - EFFECT OF SYSTEMIC STEROID PRETREATMENT [J].
BASCOM, R ;
PIPKORN, U ;
LICHTENSTEIN, LM ;
NACLERIO, RM .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 138 (02) :406-412
[2]   IMMUNE DYSREGULATION IN ATOPIC ECZEMA [J].
BOS, JD ;
WIERENGA, EA ;
SMITT, JHS ;
VANDERHEIJDEN, FL ;
KAPSENBERG, ML .
ARCHIVES OF DERMATOLOGY, 1992, 128 (11) :1509-1512
[3]   Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A [J].
Burnstine, MA ;
Elner, SG ;
Elner, VM .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (03) :318-322
[4]  
BUSINCO L, 1984, ALLERGOL IMMUNOPATH, V12, P497
[5]   Molecular events in allergic inflammation: Experimental models and possible modulation [J].
Canonica, GW ;
Ciprandi, G ;
Passalacqua, G ;
Pesce, G ;
Scordamaglia, A ;
Bagnasco, M .
ALLERGY, 1997, 52 :25-30
[6]  
Chatila Talal A., 1998, Current Opinion in Pediatrics, V10, P584
[7]  
Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1175
[8]   CETIRIZINE REDUCES INFLAMMATORY CELL RECRUITMENT AND ICAM-1 (OR CD54) EXPRESSION ON CONJUNCTIVAL EPITHELIUM IN BOTH EARLY-PHASE AND LATE-PHASE REACTIONS AFTER ALLERGEN-SPECIFIC CHALLENGE [J].
CIPRANDI, G ;
BUSCAGLIA, S ;
PESCE, G ;
PASSALACQUA, G ;
RIHOUX, JP ;
BAGNASCO, M ;
CANONICA, GW .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (02) :612-621
[9]   PROTECTIVE EFFECTS OF DEFLAZACORT ON ALLERGEN-SPECIFIC CONJUNCTIVAL CHALLENGE [J].
CIPRANDI, G ;
BUSCAGLIA, S ;
IUDICE, A ;
PESCE, GP ;
BAGNASCO, M ;
CANONICA, GW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 :S35-S41
[10]   Loratadine reduces the expression of ICAM-1 [J].
Ciprandi, G ;
Catrullo, A ;
Cerqueti, P ;
Tosca, M ;
Fiorino, N ;
Canonica, GW .
ALLERGY, 1998, 53 (05) :545-546